arrow
Μ

Μargarita Papatheodoridi

the global nash mash council
H指数:20
被引数:1,802

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort (vol 8, 101898, 2026)

慢性丁型肝炎伴轻度至中度纤维化进展为肝硬化的进程:来自多中心欧洲队列的见解(卷8,101898,2026)

2026-09-010
OA
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: insights from a multicenter European cohort.

慢性丁型肝炎伴轻度至中度纤维化进展为肝硬化的情况:来自一项多中心欧洲队列研究的见解

2026-05-190
OAAI
Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B – follow-up from the RETRACT-B cohort

慢性乙型肝炎核苷 (酸) ide类似物停止后的长期结果-RETRACT-B队列的随访

2026-03-300
OAAI
Persistent risk of hepatocellular carcinoma despite improvement of liver stiffness in chronic hepatitis B patients with advanced fibrosis

尽管肝硬度改善,慢性乙型肝炎合并进展期肝纤维化患者仍持续存在肝细胞癌风险

2025-08-200
OAAI
Long-term Bulevirtide monotherapy in patients with HDVrelated compensated cirrhosis: effectiveness, safety and clinical outcomes from the retrospective multicenter european study (Save-D)
2025-02-010
PRE
Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)

有限的持续缓解后核苷 (酸) ide类似物退出: 从慢性乙型肝炎患者的大型,全球性,多种族队列的结果 (RETRACT-B研究)

2024-05-140
PRE
Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms
2024-05-013
PRE
Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study) (vol 118, pg 1601, 2023)
2024-03-111
OA
Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 96 weeks: a retrospective multicenter european study (SAVED)
2024-02-011
PRE
HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

HBV DNA和HBsAg水平在24周关闭治疗预测临床复发和HBsAg消失在HBeAg阴性患者谁停止抗病毒治疗

2024-01-016
OA
Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study
2023-08-013
OAAI
HERACLIS-HDV cohort for the factors of underdiagnosis and prevalence of hepatitis D virus infection in HBsAg-positive patients
2023-06-084
OAAI